HFD joins American Fintech Council to push inclusive patient finance

Dallas-based HFD's AFC membership signals growing fintech pressure to reshape how healthcare costs are financed for underserved patients.

By Disrupts Editorial Team Wed, 28 October 2026 AI level 2 of 5

AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean

A brightly lit control room features numerous computer monitors displaying various data, arranged in rows along a central aisle flanked by glass-encased server racks.

Healthcare Finance Direct (HFD), a Dallas-based patient financing platform, has joined the American Fintech Council (AFC) as the trade body intensifies its push for regulatory frameworks around inclusive consumer credit. The move positions HFD alongside nearly 175 AFC member companies pressing US policymakers to standardise access to flexible financial products across healthcare, a sector where deferred treatment due to cost remains a persistent macroeconomic drag.

HFD's platform provides installment loans and pay-over-time plans to patients regardless of credit profile, with the company reporting approval rates above 99% across credit tiers. Healthcare providers using the platform receive non-recourse settlement, meaning they are protected from patient default, while patients face no credit-score impact and no down-payment requirement. The company says it has helped more than one million patients manage over $2bn in treatment costs since 2009.

Where fintech meets healthcare access

The AFC membership is largely a positioning move within Washington's regulatory arena, but it reflects a broader structural shift: embedded finance is increasingly reaching sectors that were long dominated by opaque credit products or out-of-pocket payment models. Healthcare is one of the last large consumer verticals where point-of-sale financing remains fragmented and inconsistently regulated across states.

Phil Goldfeder, CEO of the American Fintech Council, framed the partnership in explicitly systemic terms. "HFD's approach to healthcare financing allows them to look beyond traditional financial structuring and focus on getting people access to the care they need," he said, adding that the AFC plans to work with HFD on "constructing clear regulatory frameworks that help more consumers access important financial tools."

HFD's bank loan product is issued by Hatch Bank, a California-chartered industrial bank, giving the platform a regulated balance sheet behind its consumer-facing installment products. That structure sits within the bank-fintech partnership model that the AFC has championed as a preferable alternative to direct non-bank lending, a distinction that carries increasing weight as the Consumer Financial Protection Bureau continues to review earned-wage access and buy-now-pay-later products.

The convergence angle: health costs as a fintech frontier

The broader significance for cross-sector investors is the collision between fintech's regulatory maturation and healthcare's cost-access crisis. US household medical debt is estimated in the hundreds of billions of dollars, much of it held informally or consigned to collections. Fintech platforms offering structured, transparent repayment rails represent a meaningful infrastructure layer for that problem, and capital has been following: embedded healthcare finance has attracted attention from both specialist health-tech investors and generalist fintech venture funds seeking category expansion beyond payments and lending.

For healthcare providers, the economics are similarly compelling. Non-recourse financing effectively converts credit risk into a known cost of patient acquisition, improving revenue predictability without requiring providers to operate their own credit functions. That dynamic has historically attracted private-equity consolidators in dental, optometry and elective-procedure segments, who can operationalise third-party financing at scale across portfolio companies.

Regulatory clarity, which the AFC membership is partly designed to accelerate, would unlock the next phase: standardised disclosures that allow patients to compare healthcare financing products the way they compare mortgages. If the AFC succeeds in pushing a framework through, the competitive pressure on legacy medical credit card products, which carry deferred-interest structures criticised by consumer advocates, could intensify materially. For macro investors watching the intersection of US healthcare policy, consumer credit regulation and fintech infrastructure, HFD's AFC seat is a small but illustrative data point in a much larger structural trade.